Oncology | Phase I/ Phase II Developments | GERMANY

NOXXON Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NOXXON Announces Capital Increase of € 5.5 Million by Private Placement to Further Develop Its Business

Lead Product(s): NOX-A12

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: NYIP

Deal Size: $5.9 million Upfront Cash: Undisclosed

Deal Type: Financing May 08, 2020

Details:

The Financing gives the company the flexibility to consider new projects creating value with NOXXON compounds in addition to the ongoing NOX-A12 Phase 1/2 trial.

NOXXON Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NOXXON Announces That Data Safety Monitoring Board Validates NOX-A12 Dose Escalation in Phase 1/2 Brain Cancer Study

Lead Product(s): NOX-A12

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 24, 2020

Details:

Data Safety Monitoring Board (DSMB) has confirmed that it is safe to start patient recruitment for the middle dose cohort for the Phase 1/2 NOX-A12 plus radiotherapy brain cancer trial.

NOXXON Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NOXXON Secures Financing of up to € 14.2 Million Through Convertible Bonds From Atlas

Lead Product(s): NOX-A12

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Atlas Special Opportunities

Deal Size: $15.4 Million Upfront Cash: Undisclosed

Deal Type: Financing April 23, 2020

Details:

The financing would allow NOXXON to finance its clinical activities including completion of the brain cancer trial and manufacturing of additional drug supply for upcoming trials.

Affimed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24

Lead Product(s): AFM24

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Phase 1/2a clinical trial of AFM24 is a first in human study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has progressed after treatment.

NOXXON Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

NOXXON to Present Latest Clinical Data From the NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer

Lead Product(s): NOX-A12,Pembrolizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

Details:

The company presented data of its Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer.

Evotec

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse

Lead Product(s): OR2805

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: OncoResponse

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 16, 2020

Details:

Under the agreement, Just – Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic.

Medigene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

Lead Product(s): Autologous dendritic cell vaccine

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Final topline primary outcomes: DC vaccinations safe and feasible at 24 months of treatment Topline secondary outcomes: Overall survival rate of 80%, progression-free survival rate (PFS) of 55%.

Find

Find Oncology Drugs in Phase I/II Clinical Development in GERMANY

Germany

A collaboration with SCORR Marketing

Product Type

Companies

NOXXON Pharma

NOXXON Announces Capital Increase of € 5.5 Million by Private Placement to Further Develop Its Business

NOXXON Pharma

NOXXON Announces That Data Safety Monitoring Board Validates NOX-A12 Dose Escalation in Phase 1/2 Brain Cancer Study

NOXXON Pharma

NOXXON Secures Financing of up to € 14.2 Million Through Convertible Bonds From Atlas

Affimed

Affimed Announces First Patient Successfully Dosed in First-in-Human Phase 1/2A Study of AFM24

NOXXON Pharma

NOXXON to Present Latest Clinical Data From the NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer

Evotec

Just – Evotec Biologics announces product development and manufacturing agreement with OncoResponse

Medigene

Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients